Other Segment by Type to Lead Carbapenem-Based Antibiotics Market During 2021-2028

According to our latest study on "Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Product, Indication, and Distribution Channel, " the carbapenem based antibiotics market size is projected to reach US$ 5,346.62 million by 2028 from US$ 3,964.57 million in 2021; it is estimated to grow at a CAGR of 4.4% from 2021 to 2028. The report highlights the key factors and trends impacting the carbapenem based antibiotics market and focuses on prominent players and their game-changing strategies.

The rising prevalence of gram-negative bacterial infections and the increasing production of generics drugs drive the market growth. However, the tedious and expensive process for the development of antibiotics hampers the market growth.

Based on indication, the global carbapenem-based antibiotics market is segmented into bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. The others segment held the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period.

The other segment consists of skin and skin structure infections, prophylaxis of surgical site infection, gynecologic infections, and endocarditis caused by the gram-negative infections. These infections are commonly seen among people across the world. According to patient Network Safety, surgical site infections occur in 2% - 4% of surgical patients and leading cause of readmissions. However, the treatment for gram-negative infections is limited due to the emergence and spreading of carbapenem-resistant strains. Although, companies and researchers are aggressively working on the development of carbapenem-based antibiotics. Therefore, it is expected that the global carbapenem-based antibiotics market will grow rapidly in the coming years.

Pfizer Inc.; Savior Lifetec; Sumitomo Dainippon Pharma Co., Ltd.; Merck & Co., Inc.; Gland Pharma Limited; Aurobindo Pharma Ltd; Daewoong Pharmaceutical Co.,Ltd; Iterum Therapeutics plc; ACS Dobfar S.p.A; and Spero Therapeutics are among the leading companies operating in the global carbapenem-based antibiotics market.

The carbapenem-based antibiotics market for the urinary tract infections (UTI) segment is expected witness lucrative opportunities in the future owing to the high prevalence rate of UTI, which contributes to the acute pelvic infections. According to National Healthcare Safety Network, UTI is the fifth common healthcare-associated infection with 62,700 cases of UTI in acute care hospitals. Hence, these factors are expected to fuel the demand for carbapenem-based antibiotics during the forecast period.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com